KRAS and familial pancreatic carcinoma: Consistent with this, analysis of TCGA49,50 patient outcomes from pancreatic cancer, the type most frequently associated with oncogenic mutations in the KRAS gene, demonstrated that patients with mutated or down-regulated SNAP23 or VAMP3 survive longer than counterparts in whom these SNAREs are uncompromised (Fig. 6a, b; Supplementary Data 6).